The binaryleverage portfolio has slowed down during February. It has hit 41% return (since November 28th) twice in the last two weeks but both times stopped at this level and fell back. It has mirrored the NBI in this respect. The NBI is also essentially flat for February after a very strong December and January. It has been difficult to find biotech stocks approaching a catalyst that have room to appreciate given the overall rise in the market. A pullback might be helpful in bringing some of these companies valuations down a bit.